DOCSLIB.ORG

METHANOL 6 (CAS Reg

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
METHANOL 6 (CAS Reg 1 INTERIM 1: 1/2003 2 INTERIM 2: 2/2005 3 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS 4 (AEGLs) 5 METHANOL 6 (CAS Reg. No. 67-56-1) 7 For 8 NAS/COT Subcommittee for AEGLs 9 February 2005 METHANOL Interim 2: 2/2005 10 PREFACE 11 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the 12 National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances 13 (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and 14 other scientific data and develop AEGLs for high priority, acutely toxic chemicals. 15 AEGLs represent threshold exposure limits for the general public and are applicable to emergency 16 exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as 17 appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 18 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the 19 recommended exposure levels are applicable to the general population including infants and children, and 20 other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: 21 AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 22 is predicted that the general population, including susceptible individuals, could experience notable 23 discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling 24 and are transient and reversible upon cessation of exposure. 25 AEGL-2 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 26 is predicted that the general population, including susceptible individuals, could experience irreversible or 27 other serious, long-lasting adverse health effects, or an impaired ability to escape. 28 AEGL-3 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 29 is predicted that the general population, including susceptible individuals, could experience 30 life-threatening health effects or death. 31 Airborne concentrations below the AEGL-1 represent exposure levels that could produce mild and 32 progressively increasing odor, taste, and sensory irritation, or certain asymptomatic, non-sensory effects. 33 With increasing airborne concentrations above each AEGL level, there is a progressive increase in the 34 likelihood of occurrence and the severity of effects described for each corresponding AEGL level. 35 Although the AEGL values represent threshold levels for the general public, including sensitive 36 subpopulations, it is recognized that certain individuals, subject to unique or idiosyncratic responses, could 37 experience the effects described at concentrations below the corresponding AEGL level. ii METHANOL Interim 2: 2/2005 38 TABLE OF CONTENTS 39 PREFACE ......................................................................... ii 40 TABLE OF CONTENTS ............................................................ iii 41 EXECUTIVE SUMMARY ..........................................................viii 42 1. INTRODUCTION ........................................................... 1 43 2. HUMAN TOXICITY DATA ................................................... 2 44 2.1. Acute Lethality ........................................................ 2 45 2.2. Nonlethal Toxicity ...................................................... 6 46 2.2.1. Experimental Studies ............................................. 7 47 2.2.2. Occupational Exposure ............................................ 9 48 2.2.3. Case Studies ................................................... 11 49 2.3. Developmental/Reproductive Toxicity ...................................... 12 50 2.4. Genotoxicity ......................................................... 13 51 2.5. Carcinogenicity ....................................................... 13 52 2.6. Summary ............................................................ 13 53 3. ANIMAL TOXICITY DATA ................................................. 14 54 3.1. Acute Lethality ....................................................... 14 55 3.1.1. Non-human Primates ............................................ 14 56 3.1.2. Cats ......................................................... 15 57 3.1.3. Rats ......................................................... 15 58 3.1.4. Mice ......................................................... 15 59 3.2. Nonlethal Toxicity ..................................................... 17 60 3.2.1 Non-human Primates ............................................ 17 61 3.2.2. Dogs ......................................................... 19 62 3.2.3. Cats ......................................................... 19 63 3.2.4. Rats ......................................................... 19 64 3.2.5. Mice ......................................................... 20 65 3.3. Developmental/Reproductive Toxicity ...................................... 21 66 3.3.1. Nonhuman Primates ............................................. 22 67 3.3.2. Rats ......................................................... 23 68 3.3.3. Mice ......................................................... 24 69 3.4. Genotoxicity ......................................................... 25 iii METHANOL Interim 2: 2/2005 70 3.5. Carcinogenicity ....................................................... 26 71 3.6. Summary ............................................................ 26 72 4. SPECIAL CONSIDERATIONS ............................................... 27 73 4.1. Metabolism and Disposition ............................................. 27 74 4.1.1. Absorption, Distribution and Elimination ............................. 27 75 4.1.2. Metabolism .................................................... 28 76 4.1.3. Pharmacokinetic Models .......................................... 30 77 4.2. Mechanism of Toxicity ................................................. 35 78 4.3. Pharmacokinetics and Toxic Effects in Normal and Folate-Deficient Animals ........ 37 79 4.4. Structure-Activity Relationships .......................................... 39 80 4.5. Other Relevant Information .............................................. 40 81 4.5.1. Species Variability .............................................. 40 82 4.5.2. Intraspecies Variability ........................................... 40 83 4.5.3. Combination Effects ............................................. 40 84 4.5.4. Role of Folate in Human Birth Defects ............................... 40 85 5. RATIONALE AND PROPOSED AEGL-1 ...................................... 41 86 5.1. Human Data Relevant to AEGL-1 ......................................... 41 87 5.2. Animal Data Relevant to AEGL-1 ......................................... 42 88 5.3. Derivation of AEGL-1 .................................................. 42 89 6. RATIONALE AND PROPOSED AEGL-2 ...................................... 43 90 6.1. Human Data Relevant to AEGL-2 ......................................... 43 91 6.2. Animal Data Relevant to AEGL-2 ......................................... 44 92 6.3. Derivation of AEGL-2 .................................................. 45 93 7. RATIONALE AND PROPOSED AEGL-3 ...................................... 47 94 7.1. Human Data Relevant to AEGL-3 ......................................... 47 95 7.2. Animal Data Relevant to AEGL-3 ........................................ 49 96 7.3. Derivation of AEGL-3 .................................................. 50 97 8. SUMMARY OF PROPOSED AEGLS .......................................... 52 98 8.1. AEGL Values and Toxicity Endpoints ...................................... 52 99 8.2. Comparison with Other Standards and Criteria ............................... 54 100 8.3. Data Adequacy and Research Needs ....................................... 57 101 9. REFERENCES ............................................................. 58 iv METHANOL Interim 2: 2/2005 102 APPENDIX A Time Scaling Calculations for AEGLs ...................................... 69 103 AEGL-1 ................................................................... 70 104 AEGL-2 ................................................................... 71 105 AEGL-3 ................................................................... 72 106 APPENDIX B Pharmacokinetic Calculations ............................................ 73 107 Calculation of Exposure Concentrations for Humans ................................. 74 108 Comparison of the Perkins et al. (1995a) and Bouchard et al. (2001) models ............... 76 109 APPENDIX C Level of Distinct Odor Awareness ......................................... 78 110 APPENDIX D Derivation Summary for Methanol AEGLs .................................. 80 111 AEGL-1 VALUES ........................................................... 81 112 AEGL-2 VALUES ........................................................... 84 113 AEGL-3 VALUES ........................................................... 88 v METHANOL Interim 2: 2/2005 114 LIST OF TABLES 115 TABLE 1: CHEMICAL AND PHYSICAL DATA .......................................... 1 116 TABLE 2: ACUTE ORAL METHANOL INTOXICATIONS IN HUMANS ...................... 5 117 TABLE 3: SUMMARY OF EFFECTS ON HUMANS AFTER INHALATION OF METHANOL ..... 12 118 TABLE 4: SUMMARY OF ACUTE LETHAL INHALATION DATA IN LABORATORY ANIMALS 119 .........................................................................
Load more

Recommended publications
  • Perceptions of Powdered Alcohol and Intentions to Use: an Exploratory Qualitative Assessment of Potential Palcohol Use by Young Adults
    Beverages 2015, 1, 329-340; doi:10.3390/beverages1040329 OPEN ACCESS beverages ISSN 2306-5710 www.mdpi.com/journal/beverages Article Perceptions of Powdered Alcohol and Intentions to Use: An Exploratory Qualitative Assessment of Potential Palcohol Use by Young Adults John Stogner 1,*, Julie M. Baldwin 2, Timothy Brown 3 and Taylor Chick 1 1 Department of Criminal Justice and Criminology, University of North Carolina at Charlotte, 9201 University Boulevard., Charlotte, NC 28223, USA; E-Mail: [email protected] 2 Department of Criminology and Criminal Justice, Missouri State University, 901 S. National Strong Hall Room. 226, Springfield, MO 65897, USA; E-Mail: [email protected] 3 Department of Criminal Justice, University of Arkansas at Little Rock, Ross Hall 5th Floor, Little Rock, AR 72204, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-704-687-8446; Fax: +1-704-687-5285. Academic Editor: Edgar Chambers IV Received: 14 October 2015 / Accepted: 17 November 2015 / Published: 1 December 2015 Abstract: While there seems to be growing media intrigue over atypical forms of alcohol use, the utilization of the majority of novel consumption methods (e.g., eyeballing, slimming, alcohol without liquid (AWOL)) seems minimal. In 2014, however, several outlets suggested that powdered alcohol would soon surface as a threat to public safety. The impetus of these fears was the Alcohol and Tobacco Tax and Trade Bureau’s approval for Lipsmark LLC to package a powdered alcohol product named “Palcohol”. Palcohol has yet to reach store shelves, but public outcry has been intense.
    [Show full text]
  • Methanol Interim AEGL Document
    INTERIM 1: 1/2003 INTERIM 2: 2/2005 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) METHANOL (CAS Reg. No. 67-56-1) For NAS/COT Subcommittee for AEGLs February 2005 METHANOL Interim 2: 2/2005 PREFACE Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: AEGL-1 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure. AEGL-2 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.
    [Show full text]
  • Methanol: Toxicological Overview
    Methanol Toxicological Overview Key Points Kinetics and metabolism readily absorbed by all routes and distributed in the body water undergoes extensive metabolism, but small quantities are excreted unchanged by the lungs and in the urine Health effects of acute exposure methanol is toxic following ingestion, inhalation or dermal exposure exposure may initially result in CNS depression, followed by an asymptomatic latent period metabolic acidosis and ocular toxicity, which may result in blindness, are subsequent manifestations of toxicity coma and death may occur following substantial exposures long-term effects may include blindness and, following more substantial exposures, permanent damage to the CNS Health effects of chronic exposure long-term inhalation exposure to methanol has resulted in headaches and eye irritation in workers methanol is considered not to be a mutagen or carcinogen in humans methanol is considered not to be a reproductive toxicant in humans PHE publications gateway number: 2014790 Published: August 2015 Compendium of Chemical Hazards: Methanol Summary of Health Effects Methanol may be acutely toxic following inhalation, oral or dermal exposure. Acute methanol toxicity often follows a characteristic series of features; initially central nervous system (CNS) depression and gastrointestinal tract (GI) irritation may be observed. This is typically followed by a latent period of varying duration from 12–24 hours and occasionally up to 48 hours. Subsequently, a severe metabolic acidosis develops with nausea, vomiting and headache. Ocular toxicity ranges from photophobia and misty or blurred vision to markedly reduced visual acuity and complete blindness following high levels of exposure. Ingestion of as little as 4–10 mL of methanol in adults may cause permanent damage.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Choctaw Nation Criminal Code
    Choctaw Nation Criminal Code Table of Contents Part I. In General ........................................................................................................................ 38 Chapter 1. Preliminary Provisions ............................................................................................ 38 Section 1. Title of code ............................................................................................................. 38 Section 2. Criminal acts are only those prescribed ................................................................... 38 Section 3. Crime and public offense defined ............................................................................ 38 Section 4. Crimes classified ...................................................................................................... 38 Section 5. Felony defined .......................................................................................................... 39 Section 6. Misdemeanor defined ............................................................................................... 39 Section 7. Objects of criminal code .......................................................................................... 39 Section 8. Conviction must precede punishment ...................................................................... 39 Section 9. Punishment of felonies ............................................................................................. 39 Section 10. Punishment of misdemeanor .................................................................................
    [Show full text]
  • Evaluation of the Fate and Transport of Methanol in the Environment
    EVALUATION OF THE FATE AND TRANSPORT OF METHANOL IN THE ENVIRONMENT Prepared For: American Methanol Institute 800 Connecticut Avenue, NW, Suite 620 Washington, DC 20006 Prepared By: Malcolm Pirnie, Inc. 180 Grand Avenue, Suite 1000 Oakland, California 94612 JANUARY 1999 3522-002 TABLE OF CONTENTS Page EXECUTIVE SUMMARY .............................................................................................ES-1 1.0 BACKGROUND .................................................................................................... 1 1.1 Purpose and Scope of Report........................................................................ 1 1.2 Introduction and History of Use ................................................................... 1 1.3 Methanol Production..................................................................................... 3 1.4 Chemical and Physical Properties................................................................. 4 1.5 Release Scenarios ......................................................................................... 5 1.6 Fate in the Environment ............................................................................... 7 2.0 PARTITIONING OF METHANOL IN THE ENVIRONMENT........................... 9 2.1 Methanol Partitioning Between Environmental Compartments .................. 9 2.2 Air/Water Partitioning.................................................................................. 9 2.3 Soil/Water Partitioning................................................................................
    [Show full text]
  • A Case of Intentional Methanol Ingestion Sarah Gilligan MD, MS, Devin Horton MD Department of Internal Medicine, University of Utah, Salt Lake City
    A Case of Intentional Methanol Ingestion Sarah Gilligan MD, MS, Devin Horton MD Department of Internal Medicine, University of Utah, Salt Lake City To understand the complications and management of • Any methanol ingestion of more than 1 mg/kg may be • Ophtholmalogic manifestations can include methanol toxicity. lethal. mydriasis, retinal edema leading to retinal sheen, afferent pupillary defect, and, most commonly, toxic • Methanol itself is relatively non-toxic, causing only CNS optic neuropathy. depression; the more severe manifestations of methanol History of Present Illness toxicity are related to the breakdown product formic acid • Studies have shown the optimal treatment of toxic or formate. optic neuropathy is high dose solumedrol followed • 41 year old female with depression, seizure disorder, by a prednisone taper. alcohol abuse, and history of multiple suicide attempts • Metabolism of methanol: alcohol dehydrogenase oxidizes presented to the emergency department reporting that methanol to form formaldehyde which is then oxidized to • It is important to assess the mental health of she had ingested anti-freeze and alcohol and inhaled formic acid. Formic acid is oxidized to non-toxic carbon patients treated for methanol ingestion to gasoline in an attempt to commit suicide. dioxide and water by folate dependent reactions. determine intent and risk of additional self-harm. Physical Exam • Initial manifestations of methanol overdose can be mild • Successful treatment of methanol ingestion requires • Normal vital signs confusion and the appearance of intoxication. early recognition and aggressive multifactorial • Mild suprapubic tenderness medical management aimed at decreasing the levels • Laboratory testing classically shows significant metabolic • Slurred speech and inappropriate affect but alert and of methanol and its metabolites and preventing acidosis with extremely high anion gap and high osmolar answer questions long-term end organ damage.
    [Show full text]
  • Methanol Toxicity Outbreak: When Fear of COVID-19 Goes Viral
    PostScript LETTER in several other centres throughout the Patient and public involvement Patients and/or Emerg Med J: first published as 10.1136/emermed-2020-209886 on 15 May 2020. Downloaded from country during this period. the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer Unlike prior outbreaks, the current Methanol toxicity outbreak: to the Methods section for further details. outbreak of methanol poisoning appears Patient consent for publication Not required. when fear of COVID-19 to be due to the belief that consumption of disinfectants and sanitizers, specif- Provenance and peer review Not commissioned; goes viral internally peer reviewed. ically, alcohol, would be beneficial in preventing the COVID-19 infection. This This article is made freely available for use in Dear editor accordance with BMJ’s website terms and conditions is supported by several cases of methanol for the duration of the covid-19 pandemic or until Methanol ingestion can be a highly poisoning in children resulting from a otherwise determined by BMJ. You may use, download lethal poisoning; methanol is metabolised desperate attempt by parents to prevent and print the article for any lawful, non- commercial to formaldehyde and formic acid, which or cure the infection. When facing a purpose (including text and data mining) provided that all copyright notices and trade marks are retained. are extremely toxic to the central nervous serious health threat, refractory to the system and the gastrointestinal tract available remedies, such irrational deci- © Author(s) (or their employer(s)) 2020. No commercial re- use.
    [Show full text]
  • Drug and Alcohol Misuse in Havering
    JSNA Chapter: Drug and Alcohol Misuse in Havering Document details Name JSNA Drug and Alcohol Misuse in Havering Version number V6.0 Creation date 18/02/14 Status Published Lead author Louise Dibsdall (Public Health) Analysts / contributing authors Gemma Andrews (Corporate Policy and Partnerships) Mark Ansell (Public Health) Louise Dibsdall (Public Health) Rob Hayward (Public Health) Seema Patel (Public Health) Mark Ansell, Acting Director of Public Health Lead Directors Cynthia Griffin, Group Director Culture & Community Approved by JSNA Steering Group, 12th July 2014 Scheduled review date 2 years Version Draft Date Change / Approving Body V1.0 Initial draft 28th Interim progress to draft to be presented to JSNA February Steering Group 26th February 2014 2014 Amended order of chapter following feedback from 3rd March V2.0 Updated draft JSNA steering group, paying particular attention to 2014 troubled families and toxic trio. 12th March First complete draft to be presented to JSNA Steering V3.0 First full draft 2014 Group 27th March 2014 JSNA Steering Group approved progression of draft to 25th April CMT 11th April 2014. Revisions made to draft V4.0 Revised full draft 2014 following feedback from CMT; prepared for release for consultation 9th May 2014 Amendments Revisions to chapter following feedback from 30th May V5.0 following consultation exercise; submitted to JSNA Steering 2014 consultation Group for Final Approval 30th May 2014 Revised with comments from Communications team 30th June V6.0 Final and JSNA Steering Group; approved by JSNA Steering 2014 Group and signed off by Chair, 12th July 2014 Page 1 of 147 Contents Table of Figures ......................................................................................................................................
    [Show full text]
  • Reducing Substance Misuse and Related Problems: How Can Unhealthy Alcohol Users and Problem Drug Users Be Effectively Intervened with in General Hospital Settings?
    Reducing substance misuse and related problems: How can unhealthy alcohol users and problem drug users be effectively intervened with in general hospital settings? Noreen Dadirai Mdege, BPharm (Honours), MPH PhD by Publication University of York Health Sciences March 2015 Abstract Background: There is a high prevalence of unhealthy alcohol use and problem drug use among patients presenting to general hospital settings. However, many unhealthy alcohol users and problem drug users in these settings are not even aware, or do not acknowledge that they have such problems. Their presentation to hospital for the treatment of other conditions offers an opportunity to engage with them. However, there is uncertainty over how best to identify, assess and intervene with this population. Aim: To investigate how unhealthy alcohol users or problem drug users can be effectively identified, assessed and intervened with when they present to general hospital settings for the treatment of other conditions. Methods: This thesis is based on six published papers that used systematic review, meta-regression and Delphi methods. Main findings: To date, research on interventions for unhealthy alcohol use in general hospital settings has focused on brief interventions (BIs). Multiple session BIs are likely to be beneficial for unhealthy alcohol use in these settings. Where targeted screening and intervention is the strategy of choice, a focus on gastroenterology and emergency medicine is a promising way to target resources for unhealthy alcohol use. There is lack of evidence on how to effectively identify and intervene with problem drug users. The available evidence favours the ASSIST as the problem drug use screening instrument of choice.
    [Show full text]
  • Of Alcoholism Springer Berlin Heidelberg New York Barcelona Budapest Hong Kong London Milan Paris Santa Clara Singapore Tokyo M
    Acamprosate in Relapse Prevention of Alcoholism Springer Berlin Heidelberg New York Barcelona Budapest Hong Kong London Milan Paris Santa Clara Singapore Tokyo M. Soyka (Ed.) Acamprosate in Relapse Prevention of Alcoholism With 47 Figures and 16 Tables , Springer PD Dr. Michael Soyka Psychiatrische Klinik und Poliklinik der Universitat Miinchen NuBbaumstr. 7 80336 Miinchen, Germany ISBN-13 :978-3-642-80195-2 e-ISBN-13 :978-3-642-80193-8 DOl: 10.1007/978-3-642-80193-8 Library of Congress Cataloging-in-Publication Data. Acamprosate in relapse prevention of alcoholism! M.Soyka,ed. p. cm. Includes bibliographical references and index. ISBN-13:978-3-642-80195-2 (hardcover)!. Alcoholism - Chemotherapy. 2. Acamprosate. 3. Alcoholism - Relapse - Chemoprevention. I. Soyka. M. (Michael). 1959- . RC565.A27 1996 96-12923 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1996 Softcover reprint of the hardcover 1st edition 1996 The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regnlations and therefore free for general use.
    [Show full text]
  • Title 21 Amendments
    NOTICE: This document is provided as a courtesy. Recent amendments to the Cherokee Nation Code have not been officially codified. To ensure accuracy, anyone using this document should compare it to the official amendments available at: https://cherokee.legistar.com/Legislation.aspx Title 21 Amendments § 1. Title of code This title shall be known and may be cited as the Criminal Code of Cherokee Nation. § 2. Criminal acts are only those prescribed—"This code" defined No act or omission shall be deemed criminal or punishable except as prescribed or authorized by this code. The words "this code" as used in the "penal code" shall be construed to mean "Cherokee Nation Code Annotated." § 3. Crime and public offense defined A crime or public offense is an act or omission forbidden by law, and to which is annexed, upon conviction, any of the following punishments: 1. Imprisonment; 2. Fine; 3. Removal from office; 4. Disqualification to hold and enjoy any office of honor, trust, or profit, under this Nation; 5. Restitution; 6. Community service; or 7. Victim compensation assessment. § 4. Crimes classified All crimes or offenses are divided into: 1. Felonies; 2. Misdemeanors. § 5. Felony defined A felony is a crime which is, or may be, punishable by imprisonment for more than one year. § 6. Misdemeanor defined Every other crime that is not a felony is a misdemeanor. NOTICE: This document is provided as a courtesy. Recent amendments to the Cherokee Nation Code have not been officially codified. To ensure accuracy, anyone using this document should compare it to the official amendments available at: https://cherokee.legistar.com/Legislation.aspx § 7.
    [Show full text]